Create a free Feed Strategy account to continue reading

Chr. Hansen CEO Cees de Jong to step down

Chr. Hansen reports that its CEO of almost five years, Cees de Jong, will leave the company.

Chr. Hansen reports that its CEO of almost five years, Cees de Jong, will leave the company.

The company has initiated a process to find his replacement, and until then de Jong will continue as CEO of Chr. Hansen.

Ole Andersen, chairman of the company’s board of directors, said: “Cees has done a tremendous job for Chr. Hansen and its shareholders, employees and other stakeholders. Together with the corporate leadership team, Cees has steered the company while delivering in accordance with our financial goals, helped develop an ambitious strategy and been a driving force behind our initiatives to pursue new growth opportunities. Chr. Hansen will be in a much stronger shape when Cees leaves, than when he arrived. We have several new and exciting prospects. I therefore look forward to identifying and appointing a new CEO for Chr. Hansen among the very strong candidates there will naturally be for this attractive position.”

de Jong said: “Chr. Hansen has a unique competence base and strong growth prospects, and it is, and has been, a privilege to be the CEO since 2013. The company and its employees have been creating excellent results and are continuing to deliver on the ‘Nature’s No. 1’ strategy, turning Chr. Hansen into a true global microbial solutions company. While I am choosing now to pursue a different career, I will continue fully dedicated in my role as CEO for Chr. Hansen until my replacement has been found.”

Chr. Hansen is a leading, global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. It develops and produces cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. The company’s product innovation is based on more than 30,000 microbial strains –referred to as ‘good bacteria.’ Revenue in the 2016-17 financial year was EUR1,063 million. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen.

Page 1 of 178
Next Page